Announcements Trials

Browse Landscape

Phase

Phase 1 7 Phase EARLY_PHASE1 1 Phase 2 1

Status

Active not recruiting 2 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 741 Cisplatin 688 Gemcitabine 641 Bevacizumab 616 Carboplatin 605 Paclitaxel 601 Docetaxel 565 Radiotherapy 536 Fluorouracil 405 Oxaliplatin 387 Rituximab 369 Doxorubicin 361 Capecitabine 342 Filgrastim 333 Etoposide 330 Dexamethasone 312 Irinotecan 309 pembrolizumab 282 Leucovorin 274 Cetuximab 268 Cytarabine 242 Erlotinib Hydrochloride 231 Nivolumab 228 Prednisone 227 Trastuzumab 225 Vincristine 221 Bortezomib 221 Methotrexate 207 Pemetrexed 199 fludarabine phosphate 195

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × urelumab × Clear all

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Bristol-Myers Squibb

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡